Approval · Notice of Compliance 36557 · 2025
BIMZELX: Notice of Compliance 36557
Issued December 12, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36557
- Date
- December 12, 2025
- Company
- Ucb Canada IncOakville, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: The treatment of adult patients with moderate to severe hidradenitis suppurativa with an inadequate response to conventional systemic therapy.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BIMZELX | Not yet assigned | — |
Medicinal ingredients
- BIMEKIZUMAB 160 MG per ML
- BIMEKIZUMAB 320 MG per 2ML